on May 21, 2007
Published online before print May 21, 2007, doi: 10.1161/HYPERTENSIONAHA.107.088591
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on February 5, 2007
From the Burdon Sanderson Cardiac Science Centre, Department of Physiology, Anatomy & Genetics, Oxford, UK. * To whom correspondence should be addressed. E-mail: david.paterson{at}physiol.ox.ac.uk.
Abstract--Nitric oxide-cGMP pathway can inhibit cardiac norepinephrine (NE) release. Sympathetic hyper-responsiveness in hypertension may result from oxidative stress impairing this pathway. We tested the hypothesis that the gene transfer of neuronal NO synthase (nNOS) could restore sympathetic balance in the spontaneously hypertensive rat (SHR). An adenovirus (5x1010 particles) constructed with a noradrenergic neuron-specific promoter (PRS x8) encoding nNOS (Ad.PRS-nNOS) or enhanced green fluorescence protein (Ad.PRS-eGFP) was targeted to the right atrial wall by percutaneous injection in age-matched male SHRs and Wistar-Kyoto (WKY) rats. Five days after transduction, right atria were removed, and evoked [3H] norephinephrine (NE) release, NOS activity, and cGMP were measured. In the Ad.PRS-eGFP treated group, tissue levels of cGMP were significantly lower in the SHR compared with the WKY atria. NE release was also greater in the SHR, and soluble guanylate cyclase inhibition did not alter evoked [3H] NE release in the Ad.PRS-eGFP-treated SHR. All atria treated with Ad.PRS-nNOS had enhanced nNOS activity when compared with Ad.PRS-eGFP atria. Ad.PRS-nNOS in WKY rats reduced NE release compared with the Ad.PRS-eGFP group. Guanylate cyclase inhibition enhanced NE release in both Ad.PRS-nNOS- and Ad.PRS-eGFP-treated WKY atria. Ad.PRS-nNOS restored cGMP levels in the SHR to those seen in the WKY atria. In the SHR, Ad.PRS-nNOS also attenuated NE release compared with Ad.PRS-eGFP group. This was reversed by guanylate cyclase inhibition. We conclude that artificial upregulation of sympathetic nNOS via gene transfer with a noradrenergic promoter may provide a novel approach for correcting peripheral sympathetic hyperactivity in hypertension.
Revised on February 26, 2007
Noradrenergic Cell Specific Gene Transfer With Neuronal Nitric Oxide Synthase Reduces Cardiac Sympathetic Neurotransmission in Hypertensive Rats
Dan Li;
Key words: nitric oxide • gene transfer • autonomic nervous system • norepinephrine • hypertension • cyclic GMP
This article has been cited by other articles:
 |
|
 |
|
  L. Wang, D. Li, T. A. Dawson, and D. J. Paterson Long-term effect of neuronal nitric oxide synthase over-expression on cardiac neurotransmission mediated by a lentiviral vector J. Physiol., July 15, 2009; 587(14): 3629 - 3637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. R. Paton, C. J. Dickinson, and G. Mitchell Harvey Cushing and the regulation of blood pressure in giraffe, rat and man: introducing 'Cushing's mechanism' Exp Physiol, January 1, 2009; 94(1): 11 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Herring and D. J. Paterson Neuromodulators of peripheral cardiac sympatho-vagal balance Exp Physiol, January 1, 2009; 94(1): 46 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Choate, S. M. Murphy, R. Feldman, and C. R. Anderson Sympathetic control of heart rate in nNOS knockout mice Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H354 - H361. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Herring and D. J Paterson Letter by Herring and Paterson Regarding Article, "Common NOS1AP Variants Are Associated With a Prolonged QTc Interval in the Rotterdam Study" Circulation, December 11, 2007; 116(24): e564 - e564. [Full Text] [PDF]
|
|